VYNE Therapeutics (NASDAQ:VYNE) Rating Lowered to Hold at Zacks Investment Research

VYNE Therapeutics (NASDAQ:VYNEGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company’s product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey. “

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of VYNE Therapeutics in a research note on Friday, March 18th.

Shares of NASDAQ VYNE traded down $0.00 during trading on Wednesday, hitting $0.38. 552 shares of the company were exchanged, compared to its average volume of 971,018. VYNE Therapeutics has a 12-month low of $0.34 and a 12-month high of $4.24. The company has a fifty day moving average price of $0.53 and a 200-day moving average price of $0.74. The firm has a market capitalization of $21.88 million, a PE ratio of -0.40 and a beta of 1.11.

VYNE Therapeutics (NASDAQ:VYNEGet Rating) last issued its quarterly earnings data on Thursday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.09 million. VYNE Therapeutics had a negative net margin of 444.88% and a negative return on equity of 103.25%. On average, analysts anticipate that VYNE Therapeutics will post -0.63 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in VYNE. GSA Capital Partners LLP purchased a new stake in VYNE Therapeutics in the third quarter valued at approximately $128,000. Renaissance Technologies LLC raised its stake in shares of VYNE Therapeutics by 300.4% during the third quarter. Renaissance Technologies LLC now owns 1,245,027 shares of the company’s stock worth $1,731,000 after purchasing an additional 934,100 shares during the last quarter. Morgan Stanley raised its stake in shares of VYNE Therapeutics by 438.6% during the second quarter. Morgan Stanley now owns 203,075 shares of the company’s stock worth $713,000 after purchasing an additional 165,372 shares during the last quarter. Bank of America Corp DE raised its stake in shares of VYNE Therapeutics by 24.2% during the second quarter. Bank of America Corp DE now owns 149,218 shares of the company’s stock worth $524,000 after purchasing an additional 29,076 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth approximately $169,000. 22.24% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile (Get Rating)

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.

Featured Stories

Get a free copy of the Zacks research report on VYNE Therapeutics (VYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.